Hill’s Congress Blog: The FDA Should Release Its Data on Youth Use of Tobacco

The FDA needs to release its data on teen vaping. Providing a comprehensive compilation of the facts to the public will provide transparency and assure that FDA regulators’ and the administration’s policies on vaping are well-informed and impactful for the whole country. American consumers deserve to know the facts. Read this op-ed in the Hill’s […]

ACI Joins a Coalition Calling on the FDA to Release Its Data on Teen Vaping

Today, ACI joins a 14 nonprofit organizations representing both consumers and taxpayers in sending a letter to the Acting Commissioner, Norman Sharpless. This letter calls for the FDA to release its data from the 2019 National Youth Tobacco Survey before moving any further with the proposed ban on vaping products. The public deserves to know […]

Capital Hill Event: Drug Pricing Policy Prescriptions for 2020

On September 25, 2019, the American Consumer Institute held a policy briefing called “Pricing Policy Prescriptions for 2020: The Good, The Bad, and The Ugly.” The event included guest speaker John Fund, along with the following policy experts: Krisztina Pusok, Director of Policy and Research at the American Consumer Institute (moderating); Robert Graboyes is a Senior […]

Targeting E-cigarette Flavors is Blaming the Wrong Suspect

Over the last half-decade, vaping has helped reduce tobacco harm more than any other intervention. The FDA’s sweeping, knee-jerk policy change ignores the evidence and threatens to put lives at risk. Reducing the availability of flavored e-cigarettes will impose high costs on smokers while doing little to reduce vaping among teens. You can read this […]

Coalition Letter Calling on the Senate Not to End the Current Development of Quality Standards for Biologics

July 23, 2019 Dear Chairman Grassley and Ranking Member Wyden, As organizations representing American consumers, seniors, taxpayers, and free-market advocates, we are writing to express concerns over Section 207 of S. 1895, the Lower Health Care Costs Act. Many provisions of the bill would expand consumer choice, save taxpayer money, and lower out-of-pocket costs for […]

THE HILL: Public Quality Standards for Biologic Drugs Promote Transparency and Competition; Don’t Get Rid of Them

A draft of the Lower Health Care Costs Act circulated by the U.S. Senate’s powerful Health, Education, Labor, and Pensions Committee includes a provision that would drastically change how the U.S. develops standards for the strength, quality, and purity of medicines, particularly cutting-edge biologics and biosimilars. Read this op-ed at The Hill to learn why […]

ACI Coaltion Letter Sent To FDA

A coalition of nonprofit think tanks sent a letter to FDA Commissioner Sharpless urging reforms to current regulatory regulations that are impeding market competition between drug makers. The letter states that increasing market competition is the best means for price reductions, which will lower medical program costs, taxpayer burdens, and out-of-pocket expenses for consumers, as […]

Novel Financing Approaches are Needed to Capitalize on Life-Saving Gene Therapies

Today, the American Consumer Institute Center for Citizen Research (ACI) announced the release of its latest ConsumerGram, highlighting the promise of new gene replacement therapies and urging health care stakeholders to develop innovative ways of financing these important treatments. The report, authored by Dr. Joseph Fuhr, Liam Sigaud and Steve Pociask, describes the economic benefits […]